Close menu




January 29th, 2024 | 07:00 CET

Demo against the right, overtake the left with these stocks! PayPal, Saturn Oil + Gas, Evotec and Bayer

  • Mining
  • Oil
  • AI
  • Pharma
Photo credits: pixabay.com

Millions of people are on the streets, demonstrating for democracy. However, democracy also means pluralism, tolerance and fair discourse. It remains to be seen whether the politicians currently in power will eventually embrace these principles. The stock market is also a mass phenomenon, with many things developing in the same direction without much reflection. The herd instinct has both good and bad sides; on the capital markets, it often leads to irrational hype movements, as seen recently in the artificial intelligence sector. This technology is not an economic panacea either, as the elimination of jobs through the use of learning machines leads to less growth at the end of the day. As in all things, we need to use our heads, especially when it comes to the white knights of our future. Where are the opportunities for investors?

time to read: 4 minutes | Author: André Will-Laudien
ISIN: PAYPAL HDGS INC.DL-_0001 | US70450Y1038 , Saturn Oil + Gas Inc. | CA80412L8832 , EVOTEC SE INH O.N. | DE0005664809 , BAYER AG NA O.N. | DE000BAY0017

Table of contents:


    PayPal - Many promises, little innovation

    The American online payment service PayPal suffered a major setback in 2023, with its growth story stuttering in several places and investors ultimately abandoning the stock. Now, the management is going public and announcing promising news. However, with a renewed share price slump of 6% last week, the New Year offensive seems to have backfired.

    The much-anticipated Innovation Day failed to deliver new milestones, as some investors commented in forums. With a 33% online share of the US consumer landscape, the masses expected more than just a "cashback feature". Percentage rebates for reaching certain shopping thresholds are no longer a novelty, as retailers' bonus systems offer discounts in their online shops, providing consumers with many attractive coupons before their next purchase. Of course, one possible starting point is the use of AI to advance the world of personalized advertising.

    "We will set a new trend and now focus on the AI personalization of commerce," said CEO Alex Chriss in an interview. With more followers than trendsetters and clearly too little for the eager audience, the share was sold off further. A look at the Refinitiv Eikon rating platform shows 22 "Buy" recommendations out of a total of 46 ratings. The average price target is only a low USD 72.70, just 17% above the current price. Keep the stock on the watchlist until the price generates buy signals above the USD 70 mark. Before that, it lacks any attractiveness.

    Saturn Oil & Gas - Step by step into a new league

    The Canadian oil and gas specialist Saturn Oil & Gas continues to achieve great success with its new drilling techniques. The initial production results in the Cardium and Bakken light oil targets in southeastern Saskatchewan are impressive. With a 30-day average production (IP30) of approximately 233 barrels per day of light oil, the technical team is ahead of the Company's expected type curves for OHML Bakken wells in this area.

    "The strong initial production and low decline rates of the Viewfield 01-07 well are excellent indicators of the improved economics achieved through this new drilling innovation in the Canadian oil and gas sector. OHML wells require less surface space and less water compared to typical drilling and completion techniques used in the development of Bakken formations. The superior economics of OHML drilling provide access to light oil resources previously considered uneconomical and open up a broad new field for Saturn's future development," said Justin Kaufmann, Chief Development Officer.

    Saturn renegotiated its exploration credit facility in December. The amendment provided the Company with more financial flexibility to finalize its robust development plans for the fourth quarter of 2023. This allowed an additional OHML well to be drilled at the end of the year. With the new drilling locations, the output volume will increase; it stood at 26,265 barrels per day at the end of the third quarter and could develop above the 27,000 barrel mark in the first quarter. If the WTI price remains close to the USD 80 mark, an adjusted operating profit (Adj EBITDA) of around CAD 375 million is expected for 2023. Cash flow per share is estimated at CAD 2.25 per share, which is only slightly below the current market price of CAD 2.36. Saturn's low valuation continues to go unnoticed. Annual figures for 2023 will likely be published at the end of March, by which time the share price could already be above CAD 3.00. Collect up to CAD 2.50!

    Bayer and Evotec - Trading the technical rebound

    Bayer and Evoec shares are still struggling. The Leverkusen-based company has been under pressure for several years, with repeated operational setbacks and headwinds from the US lawsuits related to Monsanto's glyphosate. The takeover of the US CropScience giant caused the Bayer Group to lose a further USD 80 billion approximately in addition to the takeover price of USD 63 billion in 2016. Even worse than the billion-dollar hole of the Chrysler takeover by Daimler, this acquisition will go down in the record books of German M&A transactions with a value destruction of USD 140 billion. However, after a 5-year downward trend, Bayer may have reached an interesting level. The market capitalization is now only EUR 32 billion, with a consensus P/E ratio of 5.8 for 2024. In addition, there is a dividend of 6.4%. Risk-conscious investors are boldly moving in the EUR 31 to 33 range.

    The departure of the long-standing CEO, Dr. Werner Lanthaler, hit Evotec like a bomb. In addition to all the gloom, there are insider trading transactions dating back to 2021. These transactions were not properly reported via AdHoc and could now call BaFin, the German financial regulatory authority, into action. Hedge funds continue to impact the share price, while analysts see a buying opportunity in this non-operational issue. The Canadian bank RBC issues an "Outperform" rating with a price target of EUR 18.60, and Jefferies votes "Buy" with a 12-month price target of EUR 28. This represents an outright doubling from the current price level of EUR 14.25. Speculative investors are offering the shorties initial resistance here.

    While Bayer and PayPal remain in the red, Evotec has also entered a downward trend with the departure of its long-time CEO Lanthaler. Saturn Oil & Gas remains the only highlight. With an ever-increasing production output, its valuation is entering a new league. Source: Refinitiv Eikon from 26.01.2024

    The two indices, DAX 40 and NASDAQ100, are again up strongly in 2024. The IT and Artificial Intelligence sectors are setting the standard for excellent performance. PayPal, Bayer and Evotec are grappling with their specific challenges, while Saturn Oil & Gas consistently delivers better operational figures from one report to the next. With fundamental strength, a long-term breakout in the share price could be on the horizon.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") currently hold or hold shares or other financial instruments of the aforementioned companies and speculate on their price developments. In this respect, they intend to sell or acquire shares or other financial instruments of the companies (hereinafter each referred to as a "Transaction"). Transactions may thereby influence the respective price of the shares or other financial instruments of the Company.
    In this respect, there is a concrete conflict of interest in the reporting on the companies.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
    For this reason, there is also a concrete conflict of interest.
    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    André Will-Laudien

    Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets.

    About the author



    Related comments:

    Commented by André Will-Laudien on July 25th, 2024 | 08:20 CEST

    BioNTech, CureVac, Bayer, Cardiol Therapeutics, and Evotec: Tripled and still in turbo mode?

    • Biotechnology
    • Biotech
    • Pharma

    On the stock market, separating the wheat from the chaff is essential, especially in the biotech sector. This task becomes challenging when ongoing studies conclude, and their results must be interpreted. The market does not always react correctly to announcements, as evidenced by this year's acquisition of MorphoSys. While the stock market rejected the supposedly poor results, Novartis built up the first favourable positions, ultimately acquiring the Munich-based company for EUR 2.7 billion. From a low of around EUR 12, the acquisition price was a high EUR 68, making it a 500% deal. But opportunities are always lurking. Here is a selection of promising candidates.

    Read

    Commented by Fabian Lorenz on July 24th, 2024 | 06:30 CEST

    BioNTech, Bayer, Vidac Pharma: Buy recommendations and potential worth billions

    • Biotechnology
    • Pharma
    • Biotech

    Can BioNTech shares stop the downward trend? A "Buy" recommendation gives hope. According to this recommendation, the shares of the German biotech flagship have the potential to double in value. Analysts believe a multiplication is possible for Vidac Pharma. The biotech company is pursuing a revolutionary approach in the fight against cancer, and the first drug has a revenue potential of over EUR 1 billion. Even though research is still ongoing, Vidac is not expensive with a market capitalization of less than EUR 10 million, and is a takeover candidate if the study data remain positive. Analysts do not currently see any impetus for an increase in Bayer's share price. However, shareholders should be ready for news from the pharmaceutical pipeline in the coming weeks. These are important for the DAX-listed company.

    Read

    Commented by Fabian Lorenz on July 23rd, 2024 | 06:50 CEST

    70% with Evotec shares? Caution with BASF? Almonty Industries tempts investors to get in!

    • Mining
    • Tungsten
    • hightech
    • chemicals
    • Biotechnology

    Will BASF miss market expectations in the second half of the year? Analysts believe so. The chemical giant's revenues are already expected to fall in the second quarter. So, should one sell the shares now? The Evotec share was bought yesterday. Analysts believe that the profit warning from Sartorius should not be overestimated and see over 70% upside potential. However, patience is required. The Almonty Industries share also appears too favourable. The commissioning of a huge tungsten mine is imminent, and not only companies such as Taiwan Semiconductor and Rheinmetall need the critical metal for their high-tech products. So, when will the share break out?

    Read